SUMO-modifying Huntington's disease

被引:12
|
作者
Soares, Ericks S. [1 ]
Prediger, Rui D. [1 ,2 ]
Brocardo, Patricia S. [2 ]
Cimarosti, Helena, I [1 ,2 ]
机构
[1] Fed Univ Santa Catarina UFSC, Postgrad Program Pharmacol, Florianopolis, SC, Brazil
[2] Univ Fed Santa Catarina, Postgrad Program Neurosci, Florianopolis, SC, Brazil
来源
IBRO NEUROSCIENCE REPORTS | 2022年 / 12卷
关键词
Huntingtin; Huntington's disease; Neurodegeneration; Post-translational modification; SUMO; SUMOylation; MUTANT-HUNTINGTIN; POSTTRANSLATIONAL MODIFICATIONS; PROTEIN; SUMOYLATION; RHES; AGGREGATION; DESUMOYLATION; DEGENERATION; PATHOGENESIS; DEGRADATION;
D O I
10.1016/j.ibneur.2022.03.002
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Small ubiquitin-like modifiers, SUMOs, are proteins that are conjugated to target substrates and regulate their functions in a post-translational modification called SUMOylation. In addition to its physiological roles, SUMOylation has been implicated in several neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Huntington's diseases (HD). HD is a neurodegenerative monogenetic autosomal dominant disorder caused by a mutation in the CAG repeat of the huntingtin (htt) gene, which expresses a mutant Htt protein more susceptible to aggregation and toxicity. Besides Htt, other SUMO ligases, enzymes, mitochondrial and autophagic components are also important for the progression of the disease. Here we review the main aspects of Htt SUMOylation and its role in cellular processes involved in the pathogenesis of HD.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 50 条
  • [21] Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities
    Tabrizi, Sarah J.
    Estevez-Fraga, Carlos
    van Roon-Mom, Willeke M. C.
    Flower, Michael D.
    Scahill, Rachael I.
    Wild, Edward J.
    Munoz-Sanjuan, Ignacio
    Sampaio, Cristina
    Rosser, Anne E.
    Leavitt, Blair R.
    LANCET NEUROLOGY, 2022, 21 (07): : 645 - 658
  • [22] Disease-modifying effects of ganglioside GM1 in Huntington's disease models
    Alpaugh, Melanie
    Galleguillos, Danny
    Forero, Juan
    Morales, Luis Carlos
    Lackey, Sebastian W.
    Kar, Preeti
    Di Pardo, Alba
    Holt, Andrew
    Kerr, Bradley J.
    Todd, Kathryn G.
    Baker, Glen B.
    Fouad, Karim
    Sipione, Simonetta
    EMBO MOLECULAR MEDICINE, 2017, 9 (11) : 1537 - 1557
  • [23] Molecular characterization of genes modifying the age at onset in Huntington's disease in Uruguayan patients
    Vital, Marcelo
    Bidegain, Estela
    Raggio, Victor
    Esperon, Patricia
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2016, 126 (06) : 510 - 513
  • [24] Genetic analysis of candidate genes modifying the age-at-onset in Huntington's disease
    Metzger, Silke
    Bauer, Peter
    Tomiuk, Juergen
    Laccone, Franco
    DiDonato, Stefano
    Gellera, Cinzia
    Mariotti, Caterina
    Lange, Herwig W.
    Weirich-Schwaiger, Helga
    Wenning, Gregor K.
    Seppi, Klaus
    Melegh, Bela
    Havasi, Viktoria
    Baliko, Laszlo
    Wieczorek, Stefan
    Zaremba, Jacek
    Hoffman-Zacharska, Dorota
    Sulek, Anna
    Basak, A. Nazli
    Soydan, Esra
    Zidovska, Jana
    Kebrdlova, Vera
    Pandolfo, Massimo
    Ribai, Pascale
    Kadasi, Ludovit
    Kvasnicova, Marta
    Weber, Bernhard H. F.
    Kreuz, Friedmar
    Dose, Matthias
    Stuhrmann, Manfred
    Riess, Olaf
    HUMAN GENETICS, 2006, 120 (02) : 285 - 292
  • [25] Genetic analysis of candidate genes modifying the age-at-onset in Huntington’s disease
    Silke Metzger
    Peter Bauer
    Jürgen Tomiuk
    Franco Laccone
    Stefano DiDonato
    Cinzia Gellera
    Caterina Mariotti
    Herwig W. Lange
    Helga Weirich-Schwaiger
    Gregor K. Wenning
    Klaus Seppi
    Bela Melegh
    Viktoria Havasi
    Laszlo Balikó
    Stefan Wieczorek
    Jacek Zaremba
    Dorota Hoffman-Zacharska
    Anna Sulek
    A. Nazli Basak
    Esra Soydan
    Jana Zidovska
    Vera Kebrdlova
    Massimo Pandolfo
    Pascale Ribaï
    Ludovit Kadasi
    Marta Kvasnicova
    Bernhard H. F. Weber
    Friedmar Kreuz
    Matthias Dose
    Manfred Stuhrmann
    Olaf Riess
    Human Genetics, 2006, 120 : 285 - 292
  • [26] Huntington's disease: Neuropsychiatric manifestations of Huntington's disease
    Goh, Anita M. Y.
    Wibawa, Pierre
    Loi, Samantha M.
    Walterfang, Mark
    Velakoulis, Dennis
    Looi, Jeffrey C. L.
    AUSTRALASIAN PSYCHIATRY, 2018, 26 (04) : 366 - 375
  • [27] Stuck in the Middle: Huntington's Disease or not Huntington's Disease?
    Ziso, Besa
    Larner, Andrew J.
    Alusi, Sundus H.
    JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2015, 27 (01) : E85 - E86
  • [28] Huntington's disease: Brain imaging in Huntington's disease
    Johnson, Eileanoir B.
    Gregory, Sarah
    BRAIN IMAGING, 2019, 165 : 321 - 369
  • [29] HUNTINGTON DISEASE COMMUNITY PERSPECTIVES ON DESIRED CHARACTERISTICS OF DISEASE MODIFYING THERAPIES
    Gornick, Michele
    Ryan, Kerry
    Dayalu, Praveen
    Carlozzi, Noelle
    Albin, Roger
    Zahuranec, Darin
    MEDICAL DECISION MAKING, 2020, 40 (01) : E176 - E177
  • [30] Disease-modifying treatment approaches in Huntington disease Past and future
    Frank, Wiebke
    Lindenberg, Katrin S.
    Muhlback, Alzbeta
    Lewerenz, Jan
    Landwehrmeyer, G. Bernhard
    NERVENARZT, 2022, 93 (02): : 179 - 190